Arcturus Therapeutics Holdings (ARCT) Depreciation & Amortization (CF) (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Depreciation & Amortization (CF) of $658000.0 for Q1 2026, down 9.24% on a QoQ basis from $725000.0 in Q4 2025, and down 17.85% year-over-year from $801000.0 in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $658000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 17.85% year-over-year to $658000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (down 12.29% YoY) and the FY2025 annual result came in at $3.0 million, down 13.57% from the prior year.
- Depreciation & Amortization (CF) was $658000.0 for Q1 2026 at Arcturus Therapeutics Holdings, down from $725000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $900000.0 in Q1 2024 and bottomed at $224000.0 in Q1 2022.
- A 5-year average of $689705.9 and a median of $800000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) declined 27.04% — and 2023, when it soared 158.04%.
- Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) stood at $524000.0 in 2022, then surged by 55.53% to $815000.0 in 2023, then decreased by 1.84% to $800000.0 in 2024, then declined by 9.38% to $725000.0 in 2025, then fell by 9.24% to $658000.0 in 2026.
- Business Quant data shows ARCT's Depreciation & Amortization (CF) at $658000.0 in Q1 2026, $725000.0 in Q4 2025, and $800000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | 658,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 658,000.00 |
| Mar 31, 2026 | 658,000.00 |
| Dec 31, 2025 | 725,000.00 |
| Dec 31, 2025 | 725,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 801,000.00 |
| Mar 31, 2025 | 801,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 900,000.00 |
| Mar 31, 2024 | 900,000.00 |
| Dec 31, 2023 | 815,000.00 |
| Dec 31, 2023 | 815,000.00 |